A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
Eli Lilly and Company
Seagen Inc.
Bold Therapeutics, Inc.
TransThera Sciences (Nanjing), Inc.
Jazz Pharmaceuticals
Merck Sharp & Dohme LLC
Toray Industries, Inc
Lisata Therapeutics, Inc.
CSPC Ouyi Pharmaceutical Co., Ltd.
Galectin Therapeutics Inc.
Helsinn Healthcare SA